Market Place
Sourcing Support
PepGen Announces CONNECT Program Updates
29 Jan 2025 //
BUSINESSWIRE
FDA hits pause on another of PepGen`s muscular dystrophy trials
16 Dec 2024 //
FIERCE BIOTECH
PepGen Reports Inducement Grant for New Clinical VP Appointment
21 Nov 2024 //
BUSINESSWIRE
PepGen Reports Q3 2024 Financial Results & Corporate Highlights
07 Nov 2024 //
BUSINESSWIRE
PepGen Announces Presentations At World Muscle Society Congress
08 Oct 2024 //
BUSINESSWIRE
PepGen Announces Christopher Ashton To Retire From Board
19 Sep 2024 //
BUSINESSWIRE
PepGen Appoints Paul Streck As Executive VP, Head Of R&D
20 Aug 2024 //
BUSINESSWIRE
PepGen Announces Inducement Grant For Newly Appointed R&D Executive
20 Aug 2024 //
BUSINESSWIRE
PepGen Reports Q2 2024 Results And Corporate Highlights
08 Aug 2024 //
BUSINESSWIRE
PepGen Reports Positive Data From PGN-EDO51 Phase 2 Trial In DMD
30 Jul 2024 //
BUSINESSWIRE
PepGen Announces Executive Team Promotions
11 Jun 2024 //
BUSINESSWIRE
PepGen Reports Q1 2024 Results, Corporate Highlights
14 May 2024 //
GLOBENEWSWIRE
PepGen Receives U.S. FDA Orphan Drug Designations for PGN-EDO51
13 Mar 2024 //
GLOBENEWSWIRE
PepGen to Participate in Upcoming Investor Conferences
13 Mar 2024 //
GLOBENEWSWIRE
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
PepGen Announces Clearance of CTA to Begin CONNECT2-EDO51
04 Mar 2024 //
GLOBENEWSWIRE
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1
20 Feb 2024 //
GLOBENEWSWIRE
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
07 Feb 2024 //
GLOBENEWSWIRE
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
17 Jan 2024 //
GLOBENEWSWIRE
PepGen Announces First Patient Dosed in CONNECT1-EDO51 PII of PGN-EDO51
08 Jan 2024 //
GLOBENEWSWIRE
PepGen Announces First Patient Dosed in Phase 1 Trial of PGN-EDODM1
18 Dec 2023 //
GLOBENEWSWIRE
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
15 Nov 2023 //
GLOBENEWSWIRE
PepGen Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
PepGen Announces FDA has Lifted Clinical Hold on IND Application for PGN-EDODM1
12 Oct 2023 //
GLOBENEWSWIRE
PepGen Announces Upcoming Presentations at the 28th Annual Congress
27 Sep 2023 //
GLOBENEWSWIRE
PepGen Presents PGN-EDODM1 Data Supporting the Company`s Enhanced Delivery
06 Sep 2023 //
GLOBENEWSWIRE
PepGen Announces Clearance of CTA by Health Canada to Begin PI of PGN-EDODM1
06 Sep 2023 //
GLOBENEWSWIRE
PepGen Announces Presentations at Myotonic Dystrophy Annual Conference
01 Sep 2023 //
GLOBENEWSWIRE
PepGen Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1
13 Jun 2023 //
GLOBENEWSWIRE
FDA blocks PepGen`s attempt to get 2nd oligonucleotide to clinic
31 May 2023 //
FIERCE BIOTECH
PepGen tumbles after FDA hold notice on myotonic dystrophy study
31 May 2023 //
BIOSPACE
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application
30 May 2023 //
GLOBENEWSWIRE
PepGen Announces Clearance by Health Canada for PGN-EDO51 to Begin Phase 2 Trial
18 May 2023 //
GLOBENEWSWIRE
PepGen Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
PepGen to Participate in the Bank of America Securities 2023 Conference
04 May 2023 //
GLOBENEWSWIRE
PepGen Announces Upcoming Data at the 2023 American Academy of Neurology
17 Apr 2023 //
GLOBENEWSWIRE
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
13 Apr 2023 //
GLOBENEWSWIRE
PepGen 4Q & 2022 FYR and Recent Corporate Developments
23 Mar 2023 //
GLOBENEWSWIRE
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Conference
22 Mar 2023 //
GLOBENEWSWIRE
PepGen to Participate in the Stifel 2023 CNS Days Conference
21 Mar 2023 //
GLOBENEWSWIRE
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
16 Mar 2023 //
GLOBENEWSWIRE
PepGen Announces Upcoming Data Presentations at the 2023 Annual Conference
13 Mar 2023 //
GLOBENEWSWIRE
PepGen to Participate in the SVB Securities Global Biopharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
PepGen Inc. has seen a significant decrease in short interest.
30 Dec 2022 //
BESTSTOCKS
PepGen Announces IND-Enabling Preclinical Data Supporting of PGN-EDODM1
07 Dec 2022 //
GLOBENEWSWIRE
PepGen Announces Positive Preclinical Data PGN-EDO53, PGN-EDO45 and PGN-EDO44
14 Nov 2022 //
GLOBENEWSWIRE
PepGen Presents Data from its Duchenne Muscular Dystrophy Program
13 Oct 2022 //
GLOBENEWSWIRE
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51
28 Sep 2022 //
GLOBENEWSWIRE
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate DevP
12 Aug 2022 //
GLOBENEWSWIRE
PepGen Appoints Caroline Godfrey, Ph.D. to Company’s Scientific Advisory Board
22 Jul 2022 //
GLOBENEWSWIRE
PepGen, Inc. Joins Innovation and Collaboration Space
20 Jun 2022 //
UMASS
PepGen Reports Q1 2022 Financial Results and Corporate Developments
16 Jun 2022 //
GLOBENEWSWIRE
Newly public PepGen sees stock plunge 19%
23 May 2022 //
SEEKING ALPHA
PepGen Announces Pricing of Initial Public Offering
05 May 2022 //
GLOBENEWSWIRE
RA-backed PepGen sets terms for IPO; Sanofi commences dosing of Denali candidate
02 May 2022 //
ENDPTS
PepGen Continues to Build Leadership Team
30 Mar 2022 //
GLOBENEWSWIRE
PepGen says Approval by HC of CTA to Begin First in Human Trials of PGN-EDO51
15 Mar 2022 //
GLOBENEWSWIRE
PepGen To Present Research at Two Scientific Conferences in September
20 Sep 2021 //
GLOBENEWSWIRE
PepGen Announces New Additions to Leadership Team and Board of Directors
31 Aug 2021 //
GLOBENEWSWIRE
